Seprehvir (HSV1716)

We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

Both murine models treated with HSV1716 had significantly lower tumor burden rates compared to the controls. In conclusion, HSV1716 has potent anti-myeloma effects and may represent a novel therapy for multiple myeloma.

While expression of ligands for activating NK cell receptors was not altered on infected versus uninfected RPMI8226 and MM1S cells, a strong downregulation of CD138 with maintained CD38 expression was observed upon HSV1716 infection. The implementation of oncolytic virotherapy as an immunotherapeutic platform for cancer treatment adds a new and promising therapeutic tool for combination therapies to the treatment options of MM.

Among all OVs, oncolytic Herpes Simplex Virus (oHSV) is substantially ahead in the clinic, with an oHSV T-VEC approved by the FDA for metastatic melanoma treatment...Further, several other oHSVs including G207 and HSV1716 are currently being tested for safety and efficacy against GBM...HSV-P10 infection in combination with irradiation reduces GSC tumor sphere formation in vitro and sensitizes GBMs to radiotherapy in an intracranial mouse xenograft model. Collectively, our findings provide a potential avenue to overcome GSC-mediated therapy resistance to improve the therapeutic efficacy for GBM patients.

Results and Discussions The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Material and Methods The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Results and Discussions The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Results and Discussions The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Material and Methods The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Material and Methods The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Material and Methods The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Results and Discussions The breast cancer cells lines MCF-7 and MDA-MB-231 were infected with the herpes simplex virus (HSV1716)...This will help identify the presence of immunological and viral cargo. Future studies will aim to investigate the antitumour properties of EVs of from infected cells.

Finally, the anti-tumor effect of OV was markedly diminished when TAMs were depleted using clodronate liposomes. Together, our results show that TAMs play an essential role in support of the tumoricidal effect of the OV, HSV1716 - they both host viral replication via a novel, PCNA-dependent mechanism and are reprogramed to express a less immunosuppressive phenotype.

Here, we show that the combination of PLX4720 (BRAFV600E inhibitor) and intratumoral oncolytic herpes virus HSV1716 led to a significant tumor reduction and improved survival over single-agent treatment in a murine BRAFV600E melanoma model. Using Tocky, we are identifying specific immune subsets that are stimulated following therapy and the real-time dynamics of antigen recognition and subsequent cell activation. These findings form the basis of future testing of drug-virus combinations in an effort to identify potent cytotoxic, as well as immuno-modulatory, strategies and their detailed mechanism of action.

Indeed, using a modified herpes virus (HSV1716), we showed that direct co-culture of CC and CAFs elicits resistance to viral infection...Changes in cytokine and chemokines present in the tumor may result in changes of susceptibility to treatments like oncolytic viruses. Additionally, this could have a broader impact in the interaction between the tumor and the immune infiltrate.